Pulmonary Arterial Hypertension Treatment Market

Pulmonary arterial hypertension- commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell function- eventually elevating pressure in the pulmonary arteries responsible for pumping blood to the lungs. This eventually leads to right heart failure and, ultimately, death.

Pulmonary Arterial Hypertension Treatment Market contains market size and forecasts of Pulmonary Arterial Hypertension Treatment in Global, including the following market information:

Global Pulmonary Arterial Hypertension Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Pulmonary Arterial Hypertension Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Vasodilators Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Pulmonary Arterial Hypertension Treatment include GSK, Eli Lilly and Company, Pfizer Inc, Actelion Inc, United Therapeutic Corporation, SteadyMed Ltd, Gilead Sciences, Inc, Teva Pharmaceuticals Inc and Bayer AG. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Pulmonary Arterial Hypertension Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Pulmonary Arterial Hypertension Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Pulmonary Arterial Hypertension Treatment Market Segment Percentages, by Type, 2021 (%)

Vasodilators

Phosphodiesterase 5 (PDE 5) Inhibitors

Endothelin Receptor Antagonists (ERA)

Soluble Guanylate Cyclase (SGC) Stimulator

Global Pulmonary Arterial Hypertension Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Pulmonary Arterial Hypertension Treatment Market Segment Percentages, by Application, 2021 (%)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Pulmonary Arterial Hypertension Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Pulmonary Arterial Hypertension Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Pulmonary Arterial Hypertension Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Pulmonary Arterial Hypertension Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

GSK

Eli Lilly and Company

Pfizer Inc

Actelion Inc

United Therapeutic Corporation

SteadyMed Ltd

Gilead Sciences, Inc

Teva Pharmaceuticals Inc

Bayer AG